This Article Full Text Full Text (PDF) Supplementary Data Correction (v67,p7937) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jiao, J. Articles by Wu, H. Search for Related Content PubMed PubMed Citation Articles by Jiao, J. Articles by Wu, H.

Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development

¹ Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, California, and ² Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York

Requests for reprints: Hong Wu, Department of Molecular and Medical Pharmacology, University of California at Los Angeles School of Medicine, 650 CE Young Drive South, Los Angeles, CA 90095-1735. Phone: 310-825-5160; Fax: 310-267-0242; E-mail: hwu{at}mednet.ucla.edu.

PTEN mutations are among the most frequent genetic alterations found in human prostate cancers. Our previous works suggest that although precancerous lesions were found in Pten heterozygous mice, cancer progression and metastasis only happened when both alleles of Pten were deleted. To understand the molecular mechanisms underlying the role of PTEN in prostate cancer control, we generated two pairs of isogenic, androgen receptor (AR)–positive prostate epithelial lines from intact conditional Pten knock-out mice that are either heterozygous (PTEN-P2 and -P8) or homozygous (PTEN-CaP2 and PTEN-CaP8) for Pten deletion. Further characterization of these cells showed that loss of the second allele of Pten leads to increased anchorage-independent growth in vitro and tumorigenesis in vivo without obvious structural or numerical chromosome changes based on SKY karyotyping analysis. Despite no prior exposure to hormone ablation therapy, Pten null cells are tumorigenic in both male and female severe combined immunodeficiency mice. Furthermore, knocking down PTEN can convert the androgen-dependent Myc-CaP cell into androgen independence, suggesting that PTEN intrinsically controls androgen responsiveness, a critical step in the development of hormone refractory prostate cancer. Importantly, knocking down AR by shRNA in Pten null cells reverses androgen-independent growth in vitro and partially inhibited tumorigenesis in vivo, indicating that PTEN-controlled prostate tumorigenesis is AR dependent. These cell lines will serve as useful tools for understanding signaling pathways controlled by PTEN and elucidating the molecular mechanisms involved in hormone refractory prostate cancer formation. [Cancer Res 2007;67(13):6083–91]

This article has been cited by other articles:

				K. Song, H. Wang, T. L. Krebs, S.-J. Kim, and D. Danielpour Androgenic Control of Transforming Growth Factor-{beta} Signaling in Prostate Epithelial Cells through Transcriptional Suppression of Transforming Growth Factor-{beta} Receptor II Cancer Res., October 1, 2008; 68(19): 8173 - 8182. [Abstract] [Full Text] [PDF]

				J. A. Garcia and D. Danielpour Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies Mol. Cancer Ther., June 1, 2008; 7(6): 1347 - 1354. [Abstract] [Full Text] [PDF]

				Correction: Role of Pten in Hormone Refractory Prostate Cancer Cancer Res., August 15, 2007; 67(16): 7937 - 7937. [Full Text] [PDF]